Ligand Pharmaceuticals Incorporated (LGND)
NASDAQ: LGND · Real-Time Price · USD
209.52
-1.47 (-0.70%)
At close: Mar 18, 2026, 4:00 PM EDT
209.52
0.00 (0.00%)
After-hours: Mar 18, 2026, 4:10 PM EDT

Ligand Pharmaceuticals Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
4,1783,7392,0471,2541,1322,590
Market Cap Growth
91.16%82.62%63.27%10.73%-56.28%61.95%
Enterprise Value
3,8963,4561,7971,089930.792,572
Last Close Price
209.52189.07107.1571.4266.80154.46
PE Ratio
34.1830.84-487.0524.29-215.4846.66
Forward PE
38.0735.2053.5835.07--
PEG Ratio
2.552.423.572.34--
PS Ratio
15.5813.9512.259.555.7710.72
PB Ratio
4.073.682.471.791.903.15
P/TBV Ratio
4.183.772.361.811.893.24
P/FCF Ratio
85.4376.4421.5027.229.4436.98
P/OCF Ratio
84.6575.7421.1025.298.2132.87
EV/Sales Ratio
14.5312.8910.758.304.7410.65
EV/EBITDA Ratio
48.1246.21142.2423.5117.0616.60
EV/EBIT Ratio
82.5584.28-79.49110.91306.4824.76
EV/FCF Ratio
79.6670.6618.8723.657.7636.72
Debt / Equity Ratio
0.440.440.010.010.020.39
Debt / EBITDA Ratio
6.046.040.560.131.612.09
Debt / FCF Ratio
9.239.230.070.130.734.63
Net Debt / Equity Ratio
-0.28-0.28-0.30-0.23-0.21-0.02
Net Debt / EBITDA Ratio
-3.77-3.77-19.72-3.54-2.27-0.11
Net Debt / FCF Ratio
-5.77-5.77-2.62-3.56-1.03-0.24
Asset Turnover
0.210.210.190.170.190.18
Inventory Turnover
1.251.250.580.562.602.31
Quick Ratio
21.1821.187.9412.112.4510.24
Current Ratio
22.2322.238.9314.152.6711.15
Return on Equity (ROE)
13.47%13.47%-0.53%8.29%-0.74%9.98%
Return on Assets (ROA)
3.93%3.95%-4.89%1.45%0.63%7.20%
Return on Invested Capital (ROIC)
6.81%6.84%-6.74%1.98%0.89%10.30%
Return on Capital Employed (ROCE)
3.38%3.38%-2.70%1.37%0.32%8.25%
Earnings Yield
2.98%3.24%-0.21%4.12%-0.46%2.14%
FCF Yield
1.17%1.31%4.65%3.67%10.59%2.70%
Buyback Yield / Dilution
0.43%0.43%-4.77%-1.43%0.42%-1.09%
Total Shareholder Return
-0.43%-4.77%-1.43%0.42%-1.09%
Updated Feb 26, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q